Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A02273 | Pages: 186 | Charts: 54 | Tables: 116 |
The global Cancer Gene Therapy Market size was valued at $1.4 billion in 2020 and is projected to reach $11.4 billion by 2030, growing at a CAGR of 23.3% from 2021 to 2030. Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Cancer often has the ability to spread throughout your body. It is the second-leading cause of death in the world. Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer. Owing to the high success rate during the preclinical and clinical trials, cancer gene therapy has gained popularity. There are many techniques used for cancer gene therapy, for example, a procedure where the mutated gene is being replaced with a healthy gene or the inactivation of a gene whose function is abnormal. Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells.
[COVIDIMPACTSTATEMENT]
The key factors that boost the Cancer Gene Therapy Market growth are an increase in funding of R&D in the activities of cancer gene therapy along with the rising in the prevalence of cancer. In addition, the favorable government regulations for therapy are further going to boost various opportunities that are anticipated to provide Cancer Gene Therapy Market opportunity during the forecast period. In addition, the risk of cancer gene therapy is less, as a new gene introduced will integrate itself into the genome of the patient and continue functioning without hampering the operations of other genes are the key factors anticipating the growth of the market in upcoming years.. Hence, these aforementioned factors helps in increasing the global cancer gene therapy share. However, the high cost involved in gene therapy along with unwanted immune responses is likely to hamper the growth of the cancer gene therapy market during the forecast period.
The Gene Therapy Industry is segmented on the basis of therapy, end-user, and region. By therapy, it is categorized into gene-induced immunotherapy, oncolytic virotherapy, and gene transfer. By end-user, it is categorized into hospitals, diagnostic centers, and research institutes. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Therapy Segment Review
[THERAPYGRAPH]
By therapy, the cancer gene therapy market is categorized into oncolytic virotherapy, gene transfer, and gene-induced immunotherapy. The gene-induced immunotherapy segment dominates the market owing to the rise in the advancement of gene-induced immunotherapy research, increase in funding for R&D activities pertaining to cancer gene therapy, and rise in awareness regarding cancer gene therapy are the key factors anticipating the growth of the market in upcoming years.
End-User Segment Review
[ENDUSERGRAPH]
By end-user, the cancer gene therapy market is categorized into hospitals, diagnostic centers, and research institutes. The hospital segment was the major contributor to the global market in 2020 and is anticipated to remain dominant during the forecast period, due to the increase in healthcare awareness, rise in the number of hospitals, and growth in the geriatric and bariatric populations are the key factors anticipating the growth of the market in upcoming years..
Region Segment Review
[REGIONGRAPH]
By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America was the highest Cancer Gene Therapy Market share, with $564.52 million in 2020, and is estimated to reach $4,307.47 million by 2030, registering a CAGR of 22.5% during the forecast period. Owing to significant investments in research and advancements in technology, the Asia-Pacific market is estimated to reach $2,913.67million at a significant CAGR of 24.9%. The presence of a large population base, government initiatives to improve healthcare infrastructure, and an increase in healthcare expenditure are the key driving factors that boost the viral vectors and plasmid DNA market in the region.
The key players that operate in the cancer gene therapy market include Adaptimmune, GlaxoSmithKline, Bluebird bio, Inc., Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBionoGeneTech, SynerGene Therapeutics, and OncoGenex Pharmaceuticals.
Other prominent players in the value chain include Genelux Corporation, Cell Genesys, Advantagene, GenVec, BioCancell, Celgene, Epeius Biotechnologies, Introgen Therapeutics, Ziopharm Oncology, Shenzhen SiBionoGeneTech, and Altor Bioscience
Get more information on this report : Request Sample Pages
Key Market Segments
Key Market Players